Cantargia awards CAN10 manufacturing contract to BioInvent
Sweden-based Cantargia has awarded a contract to BioInvent International for manufacturing CAN10, a monoclonal antibody which is in preclinical development for the treatment of systemic ... Read More
Antengene gets NMPA nod for eltanexor phase 1/2 clinical trial in myelodysplastic syndrome
Antengene has been given approval from China’s National Medical Products Administration (NMPA) for a phase 1/2 clinical trial of ATG-016 (eltanexor) in myelodysplastic syndrome (MDS). ... Read More
RedHill Biopharma expands manufacturing capacity of Covid-19 drug candidate opaganib in US
RedHill Biopharma has forged partnerships with a couple of US-based manufacturers for large-scale manufacturing of opaganib, its Covid-19 drug candidate. The Israeli biopharma company said ... Read More
PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer's disease ... Read More
PostEra, NeuroLucent to partner on identifying small-molecule therapeutics for Alzheimer’s
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease ... Read More
India approves Saragene COVID-19 2-gene multiplex RT-PCR test
CoSara Diagnostics has secured clearance from the Indian Central Drugs Standard Control Organization (CDSCO) to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test. ... Read More
Merck seeks FDA and EMA approvals for V114 pneumococcal conjugate vaccine candidate
V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval ... Read More
BMS gets Opdivo EC approval for second-line treatment of ESCC
Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More
Merck to acquire OncoImmune for Covid-19 drug candidate CD24Fc
Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s ... Read More
FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11
Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More